{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:50:38Z","timestamp":1791355838612,"version":"4.3.1"},"reference-count":140,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2016.00317","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T13:37:08Z","timestamp":1471873028000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy"],"prefix":"10.3389","volume":"7","author":[{"given":"Silvia","family":"S\u00e1nchez-Ram\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Dhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chapel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V15.5.748.748","article-title":"Chronic lymphocytic leukemia, hypogammaglobulinemia and autoimmune hemolytic anemia \u2013 an experiment of nature","volume":"15","author":"Pisciotta","year":"1960","journal-title":"Blood"},{"issue":"2 Suppl","key":"B2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/1097-0142(197808)42:2+<941::AID-CNCR2820420717>3.0.CO;2-1","article-title":"Chronic lymphocytic leukemia","volume":"42","author":"Rundles","year":"1978","journal-title":"Cancer"},{"issue":"4","key":"B3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/07357908509039797","article-title":"Intravenous usage of gammaglobulin: humoral immunodeficiency, immune thrombocytopenic purpura, and newer indications","volume":"3","author":"Bussel","year":"1985","journal-title":"Cancer Invest"},{"issue":"14","key":"B4","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","volume":"319","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"B5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","article-title":"Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes","volume":"88","author":"Chapel","year":"1994","journal-title":"Br J Haematol"},{"issue":"1","key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br Med Bull"},{"issue":"5","key":"B8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"B9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"issue":"1","key":"B10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"B11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/asheducation-2003.1.438","article-title":"Infections in patients with hematological cancer: recent developments","volume":"1","author":"O\u2019Brien","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"B13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1365-2249.1992.tb06965.x","article-title":"Predictors of infection in chronic lymphocytic leukaemia (CLL)","volume":"89","author":"Griffiths","year":"1992","journal-title":"Clin Exp Immunol"},{"issue":"17","key":"B14","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1002\/cncr.29518","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"B15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4049\/jimmunol.122.3.1087","article-title":"T cell helper defect in patients with chronic lymphocytic leukemia","volume":"122","author":"Chiorazzi","year":"1979","journal-title":"J Immunol"},{"issue":"4","key":"B16","first-page":"291","article-title":"Mechanisms of infection in chronic lymphocytic leukemia","volume":"24","author":"Chapel","year":"1987","journal-title":"Semin Hematol"},{"issue":"3\u20134","key":"B17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/10428199909050963","article-title":"Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia","volume":"34","author":"Aittoniemi","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"B18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2141.1986.tb02911.x","article-title":"Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28","volume":"62","author":"Foa","year":"1986","journal-title":"Br J Haematol"},{"issue":"1","key":"B19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1600-0609.1996.tb00489.x","article-title":"Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia","volume":"57","author":"Itala","year":"1996","journal-title":"Eur J Haematol"},{"issue":"2","key":"B20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4049\/jimmunol.1402272","article-title":"Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance","volume":"194","author":"Jurado-Camino","year":"2015","journal-title":"J Immunol"},{"issue":"4","key":"B21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2003.04497.x","article-title":"Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia","volume":"122","author":"Hensel","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"B22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"2 Suppl 1","key":"B23","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immune globulin for hematologic conditions","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus Med Rev"},{"issue":"9","key":"B24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/nm0997-984","article-title":"Acquired CD40-ligand deficiency in chronic lymphocytic leukemia","volume":"3","author":"Cantwell","year":"1997","journal-title":"Nat Med"},{"issue":"2","key":"B25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/84254","article-title":"Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells","volume":"2","author":"Cerutti","year":"2001","journal-title":"Nat Immunol"},{"issue":"3","key":"B26","first-page":"698","article-title":"Hypogammaglobulinaemia associated with abnormalities of both B and T lymphocytes in patients with chronic lymphatic leukaemia","volume":"39","author":"Hersey","year":"1980","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"B27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood.V57.3.418.418","article-title":"Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation","volume":"57","author":"Kay","year":"1981","journal-title":"Blood"},{"issue":"4","key":"B28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/10428190290017033","article-title":"Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95\/CD95L in tumoral damage and escape","volume":"43","author":"Sampalo","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"B29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood"},{"issue":"6","key":"B30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1159\/000227231","article-title":"Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma","volume":"50","author":"Sklenar","year":"1993","journal-title":"Oncology"},{"issue":"8905","key":"B31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"2","key":"B32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-0609.1994.tb01874.x","article-title":"Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin","volume":"53","author":"Jurlander","year":"1994","journal-title":"Eur J Haematol"},{"issue":"2","key":"B33","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIg) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"issue":"5","key":"B34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"B36","first-page":"17","article-title":"Intravenous immune globulin in chronic lymphocytic leukaemia","volume":"97","author":"Gamm","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"B37","first-page":"1","volume-title":"Report of EMEA Expert Meeting on the Revision of the Core SPC and Note for Guidance for Human Normal Immunoglobulin for Intravenous Administration (IVIg)","author":"EMEA","year":"2008"},{"issue":"5","key":"B38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1600-0609.1992.tb01805.x","article-title":"Infections and serum IgG levels in patients with chronic lymphocytic leukemia","volume":"48","author":"Itala","year":"1992","journal-title":"Eur J Haematol"},{"issue":"1","key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/187152611794407755","article-title":"Epidemiology and management of infectious complications of contemporary management of chronic leukemias","volume":"11","author":"Young","year":"2011","journal-title":"Infect Disord Drug Targets"},{"issue":"9","key":"B40","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"B41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2141.2007.06584.x","article-title":"Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation","volume":"137","author":"Nishio","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"B42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/07357900701809068","article-title":"Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma","volume":"26","author":"Walker","year":"2008","journal-title":"Cancer Invest"},{"issue":"2","key":"B43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"B44","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/CVI.00021-11","article-title":"Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"18","author":"Karlsson","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"B45","doi-asserted-by":"publisher","first-page":"e78925","DOI":"10.1371\/journal.pone.0078925","article-title":"Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia","volume":"8","author":"Vanura","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"B46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"B47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/1042819031000063408","article-title":"Vaccination against infections in chronic lymphocytic leukemia","volume":"44","author":"Sinisalo","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"B48","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1200\/JCO.2009.26.6908","article-title":"Utility of influenza vaccination for oncology patients","volume":"28","author":"Pollyea","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"B49","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"B50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2249.2004.02439.x","article-title":"Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors","volume":"136","author":"Ferry","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"B51","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"B52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/10428194.2012.706285","article-title":"Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia","volume":"54","author":"Freeman","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"B53","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3109\/00365548.2013.809623","article-title":"Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia","volume":"45","author":"Svensson","year":"2013","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"B54","doi-asserted-by":"publisher","first-page":"e100324","DOI":"10.1371\/journal.pone.0100324","article-title":"Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement","volume":"9","author":"Duraisingham","year":"2014","journal-title":"PLoS One"},{"key":"B55","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"19","key":"B56","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"5","key":"B57","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/PPO.0b013e31826cda2d","article-title":"Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?","volume":"18","author":"Santos","year":"2012","journal-title":"Cancer J"},{"issue":"6","key":"B58","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1056\/NEJMoa075290","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"359","author":"Rawstron","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"B59","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"B60","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1365-2141.2007.06856.x","article-title":"Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology","volume":"139","author":"Dores","year":"2007","journal-title":"Br J Haematol"},{"issue":"9747","key":"B61","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"CD008079","DOI":"10.1002\/14651858.CD008079.pub2","article-title":"Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia","volume":"11","author":"Bauer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B63","doi-asserted-by":"publisher","first-page":"CD008078","DOI":"10.1002\/14651858.CD008078.pub2","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","volume":"2","author":"Skoetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"B64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ejh.12678","article-title":"Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)","volume":"96","author":"Cramer","year":"2016","journal-title":"Eur J Haematol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00043426-198608010-00019","article-title":"Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia","volume":"8","author":"Rai","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"6","key":"B66","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00296-012-2483-4","article-title":"Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases","volume":"33","author":"Besada","year":"2013","journal-title":"Rheumatol Int"},{"issue":"4","key":"B67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/ajh.23396","article-title":"The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed\/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia","volume":"88","author":"Visco","year":"2013","journal-title":"Am J Hematol"},{"issue":"12","key":"B68","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.leukres.2015.10.013","article-title":"Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study","volume":"39","author":"De Angelis","year":"2015","journal-title":"Leuk Res"},{"issue":"7","key":"B69","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(16)30045-X","article-title":"Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial","volume":"3","author":"Greil","year":"2016","journal-title":"Lancet Haematol"},{"issue":"11","key":"B70","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1634\/theoncologist.2010-0098","article-title":"Inclusion of rituximab in treatment protocols for non-Hodgkin\u2019s lymphomas and risk for progressive multifocal leukoencephalopathy","volume":"15","author":"Tuccori","year":"2010","journal-title":"Oncologist"},{"issue":"2","key":"B71","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14218\/JCTH.2016.00005","article-title":"Hepatitis B reactivation with novel agents in non-Hodgkin\u2019s lymphoma and prevention strategies","volume":"4","author":"Ozoya","year":"2016","journal-title":"J Clin Transl Hepatol"},{"issue":"18","key":"B72","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"B73","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious complications of chronic lymphocytic leukemia","volume":"33","author":"Wadhwa","year":"2006","journal-title":"Semin Oncol"},{"issue":"4","key":"B74","doi-asserted-by":"publisher","first-page":"e0122171","DOI":"10.1371\/journal.pone.0116010","article-title":"Prophylaxis and treatment of Pneumocystis jirovecii pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"key":"B75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.33590\/emjoncol\/10314554","article-title":"Rituximab and other new anti-CD20 MABs for non-Hodgkin\u2019s lymphoma treatment","volume":"2","author":"Polito","year":"2014","journal-title":"EMJ Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.2147\/TCRM.S71839","article-title":"New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab","volume":"11","author":"Shah","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"19","key":"B77","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"4","key":"B78","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"B79","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"B80","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"B81","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"B82","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"issue":"6","key":"B83","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"B84","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3466","article-title":"Primary antibody deficiencies","volume":"13","author":"Durandy","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"B85","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jaci.2015.06.031","article-title":"Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: molecular, immunologic, and clinical heterogeneity","volume":"136","author":"Perez de Diego","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"303","key":"B86","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"6","key":"B87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11864-016-0406-4","article-title":"CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia","volume":"17","author":"Singh","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"B88","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"3","key":"B89","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1053\/beha.2002.0222","article-title":"Antibody-based therapy of non-Hodgkin\u2019s lymphoma","volume":"15","author":"Foran","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"B90","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2011-03-340307","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"issue":"6","key":"B91","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1179\/1973947815Y.0000000025","article-title":"Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin\u2019s lymphoma (B-NHL) chemotherapy: a meta-analysis","volume":"27","author":"Hua","year":"2015","journal-title":"J Chemother"},{"issue":"19","key":"B92","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1055\/s-0041-102631","article-title":"[Immunoglobulin substitution in patients with indolent non-Hodgkin\u2019s lymphoma]","volume":"140","author":"Weide","year":"2015","journal-title":"Dtsch Med Wochenschr"},{"issue":"6","key":"B93","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaci.2011.08.008","article-title":"Effect of rituximab on human in vivo antibody immune responses","volume":"128","author":"Pescovitz","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2013.12.002","article-title":"The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","volume":"50","author":"Cambridge","year":"2014","journal-title":"J Autoimmun"},{"issue":"3","key":"B95","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12185-010-0528-6","article-title":"Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis","volume":"91","author":"Irie","year":"2010","journal-title":"Int J Hematol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.004","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"issue":"6","key":"B97","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"B98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"issue":"9","key":"B99","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"B100","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2011-0383","article-title":"Vaccination of oncology patients: an effective tool and an opportunity not to be missed","volume":"17","author":"Kotton","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"B102","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.blre.2015.10.001","article-title":"Vaccinations in patients with hematological malignancies","volume":"30","author":"Tsigrelis","year":"2016","journal-title":"Blood Rev"},{"issue":"12","key":"B103","doi-asserted-by":"publisher","first-page":"e114966","DOI":"10.1371\/journal.pone.0114966","article-title":"Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients\u2009\u2013 preliminary report","volume":"9","author":"Pasiarski","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"B104","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0953-6205(01)00149-2","article-title":"Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients","volume":"12","author":"van der Velden","year":"2001","journal-title":"Eur J Intern Med"},{"issue":"2","key":"B105","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3324\/haematol.2010.032664","article-title":"Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host","volume":"96","author":"de Lavallade","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"B106","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/1469-0691.12625","article-title":"Factors associated with influenza vaccination among adult cancer patients: a case-control study","volume":"20","author":"Vinograd","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 5","key":"B107","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv233.265","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"issue":"32","key":"B108","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1016\/j.vaccine.2008.04.063","article-title":"Efficacy of pneumococcal vaccination on chronic lymphocytic leukemia: should we rely on surrogate markers?","volume":"26","author":"Sinisalo","year":"2008","journal-title":"Vaccine"},{"issue":"12","key":"B109","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1017\/S0950268809991555","article-title":"Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies","volume":"138","author":"Wong","year":"2010","journal-title":"Epidemiol Infect"},{"issue":"10","key":"B110","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1080\/1042819021000015916","article-title":"Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response","volume":"43","author":"Sinsalo","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"B111","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S2255-5021(13)70002-6","article-title":"2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis","volume":"53","author":"Brenol","year":"2013","journal-title":"Rev Bras Reumatol"},{"issue":"4","key":"B112","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/030089168006600404","article-title":"Primary malignant neoplasms associated with chronic lymphocytic leukemia","volume":"66","author":"Santoro","year":"1980","journal-title":"Tumori"},{"issue":"2","key":"B113","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2014.10.028","article-title":"Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester epidemiology project population-based study in Minnesota","volume":"72","author":"Brewer","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"B114","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2141.2010.08110.x","article-title":"Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus","volume":"149","author":"Flynn","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"B115","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/leu.2012.187","article-title":"Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia","volume":"12","author":"Whitaker","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"B116","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clml.2011.07.006","article-title":"Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders","volume":"12","author":"Obeid","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"B117","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00277-008-0566-9","article-title":"Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"88","author":"Elter","year":"2009","journal-title":"Ann Hematol"},{"issue":"2","key":"B118","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CLM.2006.n.049","article-title":"Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"7","author":"O\u2019Brien","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"B119","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1038\/leu.2009.146","article-title":"Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia","volume":"23","author":"Osterborg","year":"2009","journal-title":"Leukemia"},{"issue":"19","key":"B120","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":"American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases","volume":"28","author":"Artz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"B121","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S1098-3597(06)80054-2","article-title":"Risks and consequences of chemotherapy-induced neutropenia","volume":"8","author":"Lyman","year":"2006","journal-title":"Clin Cornerstone"},{"issue":"19","key":"B122","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"B123","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/SPC.0b013e32832ea6ae","article-title":"Advances in the treatment of neutropenia","volume":"3","author":"Dale","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"issue":"6","key":"B124","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"a1831","DOI":"10.1136\/bmj.a1831","article-title":"Prescribing intravenous immunoglobulin: summary of Department of Health guidelines","volume":"337","author":"Provan","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"B126","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"issue":"10","key":"B127","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","article-title":"Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications","volume":"90","author":"Blombery","year":"2011","journal-title":"Ann Hematol"},{"issue":"10","key":"B128","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1016\/j.transproceed.2011.08.104","article-title":"Immunoglobulin prophylaxis against cytomegalovirus infection in patients at high risk of infection following allogeneic hematopoietic cell transplantation","volume":"43","author":"Ichihara","year":"2011","journal-title":"Transplant Proc"},{"issue":"1","key":"B129","doi-asserted-by":"publisher","first-page":"e2011057","DOI":"10.4084\/mjhid.2011.057","article-title":"Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation","volume":"3","author":"Khalafallah","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"Suppl 2","key":"B130","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","article-title":"Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy","volume":"164","author":"Kaveri","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"B131","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/imt.16.9","article-title":"The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?","volume":"8","author":"Corbi","year":"2016","journal-title":"Immunotherapy"},{"issue":"7","key":"B132","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fimmu.2015.00004","article-title":"Intravenous immunoglobulin and immunomodulation of B-cell \u2013 in vitro and in vivo effects","volume":"6","author":"Mitrevski","year":"2015","journal-title":"Front Immunol"},{"issue":"3A","key":"B134","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0002-9343(84)90344-9","article-title":"Use of intravenous immunoglobulin in chronic lymphocytic leukemia","volume":"76","author":"Besa","year":"1984","journal-title":"Am J Med"},{"issue":"3","key":"B135","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clim.2010.01.001","article-title":"Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg)","volume":"135","author":"Paquin-Proulx","year":"2010","journal-title":"Clin Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3389\/fimmu.2014.00637","article-title":"Persistent immune activation in CVID and the role of IVIg in its suppression","volume":"5","author":"Paquin-Proulx","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"B137","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jaut.2010.09.006","article-title":"Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies","volume":"36","author":"Bayry","year":"2011","journal-title":"J Autoimmun"},{"issue":"6","key":"B138","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2009.07669.x","article-title":"Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions","volume":"145","author":"Chapel","year":"2009","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"B139","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2249.2009.03952.x","article-title":"Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency","volume":"157","author":"Cunningham-Rundles","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B140","first-page":"1282","article-title":"National comprehensive cancer network. Non-Hodgkin\u2019s lymphomas, version 4.2014","volume-title":"J Natl Compr Canc Netw","author":"Zelenetz","year":"2014"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T20:05:28Z","timestamp":1692475528000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fimmu.2016.00317\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":140,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2016.00317","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,22]]}}}